All GLG News Analyses Filed Under: Cardiology
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?
November 15, 2009
Another Vytorin Mess For Merck | www.forbes.com
Abbott Laboratories' (ABT.N) Niaspan, though inexpensive and older, lowered HDL and shrunk artery diameter in heart patients more effectively and safely than Merck & Co's (MRK.N) moderately expensive Zetia.Though there is little reason for doctors to prescribe Zetia now, there are real cautions about...
-
Percutaneous valve repair – next battle among cardiovascular device companies?
October 4, 2009
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com
By acquiring promising technology in the percutaneous valve arena, as well as enjoying an already established reputation among interventional cardiologists, Abbott will position itself as a major player in an emerging technology market, and become a comprehensive provider for interventional cardiology...
-
Will the alternative become a leader?
October 1, 2009
EMEA recommends approval of Sanofi-aventis' dronedarone for atrial fibrillation | www.pharmabiz.com
Introducing dronedarone in treatment of atrial fibrillation will provide solution for many patients with atrial fibrillation who were undertreated due to their contraindications for amiodarone or it's adverse effects.
-
A new treatment for a major problem.
September 30, 2009
ACC: Device May Prevent Stroke in AF Patients | www.medpagetoday.com
Atrial fibrillation is a very common condition that significantly increase the risk of stroke, especially in the older population. Vitamin K antagonists are the only current effective treatment in the higher risk population to reduce stroke. Any new treatment has a huge potential to help reduce risk,...
-
How much market will MADIT-CRT drive?
September 30, 2009
Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events | content.nejm.org
While this trial had a positive endpoint, it was not a mortality endpoint. A major defect is a lack of a medical therapy alone arm. That said, prevention of heart failure episodes is a laudable goal and given the expense to the US system of CHF, this could be a worthwhile treatment, however thenumber...
-
Convenient for patients, and maybe for doctors
September 26, 2009
Novartis gets FDA approval for combo pill valturna to treat high BP | www.pharmabiz.com
Undoubtedly powerful combination which will help control BP in many patients who have resistant or difficult to control hypertension.
-
September 21, 2009
Novartis gets FDA approval for combo pill valturna to treat high BP | /councils.glgroup.com/news/ExternalLink.mvc/Article/303185?utm_campaign=newswatch
The FDA have approved a combination of Aliskiren and Valsartan in a fixed dose preparation for the treatment of hypertension. Although initial safety data show efficacy and tolerability in an 8-week study, outcome data on real-life use and in "non-standard" cases of hypertension or other disorderssuggests...
-
The Logical Next Step for Abbott
September 15, 2009
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com
With this acquisition Abbott establishes its position as a major player in the field of interventional cardiology and treatment of structural heart disease.The field of structural heart disease therapy is the fastest growing area of interventional cardiology and Abbott is getting in at the ground floor.In...
-
Abbot will benefit in long run with acquisition of Evalve.
September 15, 2009
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com
The acquisition will definitely have a significantly beneficial effect on the market standing as well as product portfolio of Abbot. Even though at the present time this technique developed by Evalve Inc. is useful only for a very small subset of patients, eventually Abbott can develop it furtherto...
-
September 14, 2009
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com
Good ideas and good products are better improved and marketed as a products of a large company, but....
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Healthcare News
-
Mobile Advertising Set To Soar ? Yes, But What Is The Engine For Growth
November 17, 2009
-
Roche Receives H1N1 FDA Emergency Use Authorization
November 16, 2009
-
From a physician point of view
November 16, 2009
-
Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?
November 15, 2009
-
November 15, 2009
-
www.medscape.com
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today
-
www.medicalnewstoday.com
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology
-
www.pipelinereview.com
-
www.nytimes.com
-
www.docguide.com
FDA: Ongoing Omalizumab Study Shows Increased Number of Cardiovascular Events